Where can I buy CLVS shares?
May 04, 2022 · Real-time trade and investing ideas on Clovis Oncology Inc CLVS from the largest community of traders and investors.
How profitable is Clovis Oncology (CLVS) stock?
Apr 15, 2022 · In the past three months, Clovis Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19.00 in company stock. Percentage Held by Insiders. Only 5.40% of the stock of Clovis Oncology is held by insiders.
Is CLVS a scam?
Real time Clovis Oncology (CLVS) stock price quote, stock graph, news & analysis.
What is the difference between CLVS and Novartis’s cancer treatment?
May 06, 2022 · Complete Clovis Oncology Inc. stock information by Barron's. View real-time CLVS stock price and news, along with industry-best analysis.
Is Clvs a good investment?
Is Clovis Oncology a good stock?
Is Clvs a shorted stock?
This table shows the number of shares of US:CLVS available to be shorted at a leading prime brokerage.
Why is Clvs shorted?
Will Clvs stock go up?
The 3 analysts offering 12-month price forecasts for Clovis Oncology Inc have a median target of 3.00, with a high estimate of 4.00 and a low estimate of 1.50. The median estimate represents a +201.36% increase from the last price of 1.00.
Is Clovis a buy right now?
...
Score -2.625.
| Low | Average | High |
|---|---|---|
| $4.00 | $4.00 | $4.00 |
Who owns Clvs?
How much is Clvs shorted?
| Clovis Oncology Incorporated | $ 1.53 |
|---|---|
| CLVS (NASDAQ) | -0.15 |
How do you buy stocks on wish?
Is Clovis Oncology a buy right now?
2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 1...
How has Clovis Oncology's stock price been impacted by COVID-19?
Clovis Oncology's stock was trading at $6.17 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization....
When is Clovis Oncology's next earnings date?
Clovis Oncology is scheduled to release its next quarterly earnings announcement on Wednesday, May 4th 2022. View our earnings forecast for Clovis...
How were Clovis Oncology's earnings last quarter?
Clovis Oncology (NASDAQ:CLVS) announced its earnings results on Tuesday, February, 22nd. The biopharmaceutical company reported ($0.50) EPS for the...
What price target have analysts set for CLVS?
2 brokers have issued 1 year target prices for Clovis Oncology's stock. Their forecasts range from $4.75 to $5.00. On average, they anticipate Clov...
Who are Clovis Oncology's key executives?
Clovis Oncology's management team includes the following people: Mr. Patrick J. Mahaffy MA , Co-Founder, Chief Exec. Officer, Pres and Exec. Dire...
What is Patrick J. Mahaffy's approval rating as Clovis Oncology's CEO?
12 employees have rated Clovis Oncology CEO Patrick J. Mahaffy on Glassdoor.com . Patrick J. Mahaffy has an approval rating of 49% among Clovis On...
Who are some of Clovis Oncology's key competitors?
Some companies that are related to Clovis Oncology include Amgen (AMGN) , Regeneron Pharmaceuticals (REGN) , Gilead Sciences (GILD) , Vertex Ph...
What other stocks do shareholders of Clovis Oncology own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GIL...
Is Clovis Oncology a buy right now?
What stocks does MarketBeat like better than Clovis Oncology?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Clovis Oncology stock.
When is Clovis Oncology's next earnings date?
Wall Street analysts have given Clovis Oncology a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Clovis Oncology wasn't one of them.
How were Clovis Oncology's earnings last quarter?
Clovis Oncology is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.#N#View our earnings forecast for Clovis Oncology.
How has Clovis Oncology's stock been impacted by Coronavirus?
Clovis Oncology (NASDAQ:CLVS) released its quarterly earnings data on Wednesday, August, 4th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by $0.04.#N#View Clovis Oncology's earnings history.
What price target have analysts set for CLVS?
Clovis Oncology's stock was trading at $6.17 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CLVS shares have decreased by 29.8% and is now trading at $4.33.#N#View which stocks have been most impacted by COVID-19.
What is Patrick J. Mahaffy's approval rating as Clovis Oncology's CEO?
4 equities research analysts have issued 12-month target prices for Clovis Oncology's shares. Their forecasts range from $3.00 to $10.00. On average, they anticipate Clovis Oncology's stock price to reach $6.00 in the next year.
Major Holders
12 employees have rated Clovis Oncology CEO Patrick J. Mahaffy on Glassdoor.com. Patrick J. Mahaffy has an approval rating of 49% among Clovis Oncology's employees. This puts Patrick J. Mahaffy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
Financials
Copyright 2020 FactSet Research Systems Inc. All rights reserved. Source: FactSet Fundamentals
Signals & Forecast
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock quotes are delayed as per exchange requirements. Fundamental company data and analyst estimates provided by FactSet.
Support, Risk & Stop-loss
There are mixed signals in the stock today. The Clovis Oncology stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Is Clovis Oncology stock A Buy?
Clovis Oncology finds support from accumulated volume at $4.40 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
